Anti-DLL3 antibody drug conjugates
US9481727B2 · kind B2 · utility
2Cited by
47References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 21, 2016 |
| Grant date | Nov 1, 2016 |
| Priority date | — |
| Expiry date | Apr 21, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.